TG Therapeutics, Inc.
Nasdaq TGTX · New York, NY
Works in Cardiovascular · Hematology · Immunology · Neurology · Oncology · Ophthalmology · Psychiatry
TG Therapeutics, Inc. is a clinical trial sponsor based in New York, NY, listed as Nasdaq TGTX. It has 12 active clinical trials with 5,906 planned participants, across 7 therapeutic areas. Since 2021 it has completed 11 trials and stopped 13 early.
Trial track record · since 2021
Financials · Nasdaq TGTX
Pipeline · 12 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about TG Therapeutics, Inc
TG Therapeutics, Inc is lead sponsor of 12 active clinical trials on ClinicalTrials.gov, with 5,906 planned participants, in Cardiovascular, Hematology, Immunology, Neurology and other areas. Since 2021 it has completed 11 trials and stopped 13 early.
TG Therapeutics, Inc is based in New York, NY and is listed as Nasdaq TGTX. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with TG Therapeutics, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-24.
Approve Suite is not affiliated with TG Therapeutics, Inc.. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.